Infected sites | Doxycycline + ceftriaxone (n = 61) | Doxycycline + cefixime (n = 64) | ORs (95% CI) | p value | ||
---|---|---|---|---|---|---|
n | % (95% CI) | n | % (95% CI) | |||
Subjects eradicated CT | ||||||
Genital | 36 | 100.0 | 41 | 100.0 | 1 | |
Pharyngeal | 12 | 100.0 | 4 | 57.1 | 0.036 | |
Rectal | 4 | 100.0 | 6 | 100.0 | 1 | |
Genital + pharyngeal | 6 | 75.0 | 4 | 66.7 | 1.46 (0.1–28.6) | 1 |
Rectal + pharyngeal | 0 | 1 | 25.0 | 1 | ||
All sites | 58 | 95.1 (86.5–98.3) | 56 | 87.5 (77.2–93.5) | 2.7 (0.6–16.8) | 0.21 |
Subjects eradicated NG | ||||||
Genital | 36 | 100.0 | 41 | 100.0 | 1 | |
Pharyngeal | 12 | 100.0 | 6 | 85.7 | 0.37 | |
Rectal | 4 | 100.0 | 6 | 100.0 | 1 | |
Genital + pharyngeal | 6 | 75 | 5 | 83.3 | 0.6 (0.1–15.5) | 1 |
Rectal + pharyngeal | 1 | 100.0 | 3 | 75.0 | 1 | |
All sites | 59 | 96.7 (88.8–99.1) | 61 | 95.3 (87.1–98.4) | 1.45 (0.16–17.89) | 1 |
Subjects eradicated CT and NG | ||||||
Genital | 36 | 100.0 | 41 | 100.0 | 1 | |
Pharyngeal | 12 | 100.0 | 3 | 42.9 | 0.009 | |
Rectal | 4 | 100.0 | 5 | 83.3 | 1 | |
Genital + pharyngeal | 6 | 75.0 | 2 | 33.3 | 5.2 (0.4–108.1) | 0.28 |
Rectal + pharyngeal | 0 | 0.0 | 1 | 25.0 | 1 | |
All sites | 58 | 95.1 (86.5–98.3) | 52 | 81.2 (70.0–88.9) | 4.41 (1.11–25.7) | 0.026 |